Literature DB >> 25580906

Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.

Maria V Papadopoulou1, William D Bloomer, Galina I Lepesheva, Howard S Rosenzweig, Marcel Kaiser, Benjamín Aguilera-Venegas, Shane R Wilkinson, Eric Chatelain, Jean-Robert Ioset.   

Abstract

3-Nitro-1H-1,2,4-triazole-based amides with a linear, rigid core and 3-nitrotriazole-based fluconazole analogues were synthesized as dual functioning antitrypanosomal agents. Such compounds are excellent substrates for type I nitroreductase (NTR) located in the mitochondrion of trypanosomatids and, at the same time, act as inhibitors of the sterol 14α-demethylase (T. cruzi CYP51) enzyme. Because combination treatments against parasites are often superior to monotherapy, we believe that this emerging class of bifunctional compounds may introduce a new generation of antitrypanosomal drugs. In the present work, the synthesis and in vitro and in vivo evaluation of such compounds is discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25580906      PMCID: PMC4337820          DOI: 10.1021/jm5015742

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

1.  Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Spencer Anderson; Yuliya Kleshchenko; Vyacheslav Furtak; Zdzislaw Wawrzak; Fernando Villalta; Michael R Waterman
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 2.  Chagas disease.

Authors:  Anis Rassi; Anis Rassi; José Antonio Marin-Neto
Journal:  Lancet       Date:  2010-04-17       Impact factor: 79.321

3.  Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Eric Chatelain; Marcel Kaiser; Shane R Wilkinson; Caroline McKenzie; Jean-Robert Ioset
Journal:  J Med Chem       Date:  2012-05-23       Impact factor: 7.446

4.  Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.

Authors:  Maria V Papadopoulou; Bernadette Bourdin Trunz; William D Bloomer; Caroline McKenzie; Shane R Wilkinson; Chaiya Prasittichai; Reto Brun; Marcel Kaiser; Els Torreele
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

5.  Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans.

Authors:  B H Stewart; O H Chan; R H Lu; E L Reyner; H L Schmid; H W Hamilton; B A Steinbaugh; M D Taylor
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

6.  Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.

Authors:  Grasiella Andriani; Emanuele Amata; Joel Beatty; Zeke Clements; Brian J Coffey; Gilles Courtemanche; William Devine; Jessey Erath; Cristin E Juda; Zdzislaw Wawrzak; Jodianne T Wood; Galina I Lepesheva; Ana Rodriguez; Michael P Pollastri
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

7.  CYP51: A major drug target in the cytochrome P450 superfamily.

Authors:  Galina I Lepesheva; Tatyana Y Hargrove; Yuliya Kleshchenko; W David Nes; Fernando Villalta; Michael R Waterman
Journal:  Lipids       Date:  2008-09-04       Impact factor: 1.880

8.  VNI cures acute and chronic experimental Chagas disease.

Authors:  Fernando Villalta; Mark C Dobish; Pius N Nde; Yulia Y Kleshchenko; Tatiana Y Hargrove; Candice A Johnson; Michael R Waterman; Jeffrey N Johnston; Galina I Lepesheva
Journal:  J Infect Dis       Date:  2013-01-31       Impact factor: 5.226

9.  Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

Authors:  Galina I Lepesheva; Robert D Ott; Tatiana Y Hargrove; Yuliya Y Kleshchenko; Inge Schuster; W David Nes; George C Hill; Fernando Villalta; Michael R Waterman
Journal:  Chem Biol       Date:  2007-11

10.  Ergosterol biosynthesis and drug development for Chagas disease.

Authors:  Julio A Urbina
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

View more
  12 in total

1.  Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.

Authors:  Yunfei An; Yue Dong; Liu Min; Liyu Zhao; Dongmei Zhao; Jun Han; Bin Sun
Journal:  ACS Med Chem Lett       Date:  2020-05-11       Impact factor: 4.345

2.  Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment In Vivo Assay.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Ana Lia Mazzeti; Karolina Ribeiro Gonçalves; Priscila Fagundes Mendes; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Quinolone Amides as Antitrypanosomal Lead Compounds with In Vivo Activity.

Authors:  Georg Hiltensperger; Nina Hecht; Marcel Kaiser; Jens-Christoph Rybak; Alexander Hoerst; Nicole Dannenbauer; Klaus Müller-Buschbaum; Heike Bruhn; Harald Esch; Leane Lehmann; Lorenz Meinel; Ulrike Holzgrabe
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.

Authors:  William J Hoekstra; Tatiana Y Hargrove; Zdzislaw Wawrzak; Denise da Gama Jaen Batista; Cristiane F da Silva; Aline S G Nefertiti; Girish Rachakonda; Robert J Schotzinger; Fernando Villalta; Maria de Nazaré C Soeiro; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

5.  Combined Strategies to Improve the Expression of Recombinant Sterol C24-Methyltransferase from Leishmania braziliensis in E. coli.

Authors:  Humberto F Freitas; Acássia Benjamim Leal Pires; Marcelo S Castilho
Journal:  Mol Biotechnol       Date:  2018-04       Impact factor: 2.695

6.  Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans.

Authors:  Elizabeth W Hunsaker; Katherine J McAuliffe; Katherine J Franz
Journal:  J Biol Inorg Chem       Date:  2020-06-15       Impact factor: 3.358

7.  Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies.

Authors:  Pedro Igor Camara de Oliveira; Paulo Henrique de Santana Miranda; Estela Mariana Guimaraes Lourenço; Priscilla Suene de Santana Nogueira Silverio; Euzebio Guimaraes Barbosa
Journal:  Mol Divers       Date:  2020-06-16       Impact factor: 2.943

8.  Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Shane R Wilkinson; Joanna Szular; Marcel Kaiser
Journal:  Eur J Med Chem       Date:  2016-04-08       Impact factor: 6.514

9.  Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Shane R Wilkinson; Joanna Szular; Marcel Kaiser
Journal:  Eur J Med Chem       Date:  2016-08-09       Impact factor: 6.514

Review 10.  An insight on medicinal attributes of 1,2,4-triazoles.

Authors:  Ranjana Aggarwal; Garima Sumran
Journal:  Eur J Med Chem       Date:  2020-07-27       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.